The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+ breast cancer.
Khashayar Esfahani
No relevant relationships to disclose
Cristiano Ferrario
No relevant relationships to disclose
Philippe Le
No relevant relationships to disclose
Lawrence C. Panasci
No relevant relationships to disclose